ATE535245T1 - Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis - Google Patents

Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis

Info

Publication number: ATE535245T1
Authority: AT; Austria
Prior art keywords: group; psoriasis; treat psoriasis; polyunsaturated ketones; hydrocarbon group
Prior art date: 2002-01-29

Application number

AT03704739T

Other languages

English (en)

Inventor

Berit Johansen

Marit Anthonsen

Wenche Sjursen

Anne Kristen Holmeide

Lars Skattebol

Original Assignee

Avexxin As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-29

Filing date

2003-01-29

Publication date

2011-12-15

2003-01-29 Application filed by Avexxin As filed Critical Avexxin As

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE535245T1 publication Critical patent/ATE535245T1/de

Links

201000004681 Psoriasis Diseases 0.000 title abstract 3
150000002576 ketones Chemical class 0.000 title 1
125000005842 heteroatom Chemical group 0.000 abstract 2
125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000006575 electron-withdrawing group Chemical group 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
208000017520 skin disease Diseases 0.000 abstract 1
229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT03704739T 2002-01-29 2003-01-29 Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis ATE535245T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0202002.2A GB0202002D0 (en)	2002-01-29	2002-01-29	Use
PCT/GB2003/000364 WO2003063878A1 (en)	2002-01-29	2003-01-29	Use of polyunsaturated ketones for the treatment of psoriasis

Publications (1)

Publication Number	Publication Date
ATE535245T1 true ATE535245T1 (de)	2011-12-15

Family

ID=9929945

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03704739T ATE535245T1 (de)	2002-01-29	2003-01-29	Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis

Country Status (14)

Country	Link
US (4)	US7687543B2 (de)
EP (1)	EP1469859B1 (de)
JP (1)	JP4608214B2 (de)
KR (1)	KR100874505B1 (de)
CN (2)	CN1678323A (de)
AT (1)	ATE535245T1 (de)
AU (1)	AU2003206999B2 (de)
CA (1)	CA2473687C (de)
DK (1)	DK1469859T3 (de)
ES (1)	ES2378303T3 (de)
GB (1)	GB0202002D0 (de)
NO (1)	NO334413B1 (de)
PT (1)	PT1469859E (de)
WO (1)	WO2003063878A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2248798A1 (de) *	2009-05-08	2010-11-10	Pronova BioPharma Norge AS	Neue Lipidverbindungen
GB0909643D0 (en) *	2009-06-04	2009-07-22	Avexxin As	Glomerulonephritis treatment
EP2482815B1 (de) *	2009-10-02	2018-05-02	Avexxin AS	Antiinflammatorische 2-oxothiazole und 2-oxooxazole
GB201014633D0 (en)	2010-09-02	2010-10-13	Avexxin As	Rheumatoid arthritis treatment
ES2618604T3 (es)	2010-11-05	2017-06-21	Pronova Biopharma Norge As	Métodos de tratamiento usando compuestos lipídicos
GB201205394D0 (en)	2012-03-27	2012-05-09	Adlens Ltd	Improvements in or relating to deformable non-round membrane assemblies
GB201221329D0 (en) *	2012-11-27	2013-01-09	Avexxin As	Dermatitis treatment
EP2951164B1 (de)	2013-01-29	2019-06-05	Avexxin AS	Entzündungshemmende und antitumorwirkende 2-oxothiazolverbindungen
MX377728B (es)	2013-02-28	2025-03-11	Pronova Biopharma Norge As	Composición que comprende un compuesto lípido, un triglicerido y un tensioactivo, y métodos de uso de la misma.
GB201313238D0 (en)	2013-07-24	2013-09-04	Avexxin As	Process for the preparation of a polyunsaturated ketone compound
GB201409363D0 (en) *	2014-05-27	2014-07-09	Avexxin As	Skin cancer treatment
GB201413695D0 (en)	2014-08-01	2014-09-17	Avexxin As	Compound
GB201501144D0 (en)	2015-01-23	2015-03-11	Avexxin As	Process for the preparation of a polyunsaturated ketone compound
ES2980790T3 (es)	2015-04-28	2024-10-03	Basf As	Acidos grasos estructuralmente mejorados que contienen azufre para su uso en el tratamiento de la esteatohepatitis no alcohólica
GB201604316D0 (en)	2016-03-14	2016-04-27	Avexxin As	Combination therapy
GB201604318D0 (en)	2016-03-14	2016-04-27	Avexxin As	Combination therapy
CN109310771A (zh) *	2016-06-03	2019-02-05	埃维克辛公司	包含多不饱和酮与皮质甾类化合物的联合疗法
GB201609735D0 (en) *	2016-06-03	2016-07-20	Avexxin As	Combination therapy
JP2019517525A (ja) *	2016-06-03	2019-06-24	アヴェクシンエーエス	多価不飽和ケトン及びセコステロイドを含む併用療法
US20200323793A1 (en) *	2016-06-03	2020-10-15	Avexxin As	Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor
CN109789111B (zh) *	2016-09-21	2021-11-16	埃维克辛公司	药物组合物
CA3067302A1 (en) *	2017-06-16	2018-12-20	Avexxin As	Compositions and methods for treatment of a fibrotic disease
IL308604B2 (en)	2017-12-06	2025-08-01	Basf As	Fatty acid derivatives for treating non-alcoholic steatohepatitis
GB201807892D0 (en)	2018-05-15	2018-06-27	Avexxin As	Processes in the preparation of polyunsaturated ketone compounds
GB202020843D0 (en)	2020-12-31	2021-02-17	Coegin Pharma Ab	Actinic keratosis treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09268153A (ja) *	1996-04-02	1997-10-14	Sagami Chem Res Center	トリフルオロメチルケトン誘導体及びホスホリパーゼａ２阻害剤
EP1140791A4 (de) *	1997-09-23	2001-10-10	Bristol Myers Squibb Co	Selektive cpla2-inhibitoren
JPH11199493A (ja) *	1997-11-13	1999-07-27	Nof Corp	皮膚外用剤組成物
US7605149B1 (en)	1998-07-13	2009-10-20	University Of South Florida	Modulation of the phospholipase A2 pathway as a therapeutic
US20020165119A1 (en) *	2001-01-31	2002-11-07	Alan Leff	Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2
EP1243524A3 (de) *	2001-03-16	2004-04-07	Pfizer Products Inc.	Pharmazeutisches Kit fÜr sauerstoffempfindliche Medikamente
US20040111957A1 (en) *	2002-12-13	2004-06-17	Filippini Brian B.	Water blended fuel composition

2002
- 2002-01-29 GB GBGB0202002.2A patent/GB0202002D0/en not_active Ceased
2003
- 2003-01-29 AU AU2003206999A patent/AU2003206999B2/en not_active Ceased
- 2003-01-29 JP JP2003563568A patent/JP4608214B2/ja not_active Expired - Fee Related
- 2003-01-29 CA CA2473687A patent/CA2473687C/en not_active Expired - Fee Related
- 2003-01-29 KR KR1020047011693A patent/KR100874505B1/ko not_active Expired - Fee Related
- 2003-01-29 CN CNA038028999A patent/CN1678323A/zh active Pending
- 2003-01-29 US US10/502,414 patent/US7687543B2/en not_active Expired - Fee Related
- 2003-01-29 AT AT03704739T patent/ATE535245T1/de active
- 2003-01-29 EP EP03704739A patent/EP1469859B1/de not_active Expired - Lifetime
- 2003-01-29 CN CN201010129984A patent/CN101849929A/zh active Pending
- 2003-01-29 ES ES03704739T patent/ES2378303T3/es not_active Expired - Lifetime
- 2003-01-29 PT PT03704739T patent/PT1469859E/pt unknown
- 2003-01-29 WO PCT/GB2003/000364 patent/WO2003063878A1/en not_active Ceased
- 2003-01-29 DK DK03704739.6T patent/DK1469859T3/da active
2004
- 2004-08-25 NO NO20043548A patent/NO334413B1/no not_active IP Right Cessation
2010
- 2010-02-26 US US12/713,917 patent/US8524776B2/en not_active Expired - Fee Related
2013
- 2013-08-02 US US13/957,899 patent/US8865768B2/en not_active Expired - Lifetime
2014
- 2014-09-16 US US14/487,382 patent/US9375409B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2005518419A (ja)	2005-06-23
US8865768B2 (en)	2014-10-21
CN101849929A (zh)	2010-10-06
EP1469859A1 (de)	2004-10-27
US9375409B2 (en)	2016-06-28
US20050165116A1 (en)	2005-07-28
JP4608214B2 (ja)	2011-01-12
CA2473687A1 (en)	2003-08-07
NO334413B1 (no)	2014-02-24
EP1469859B1 (de)	2011-11-30
US7687543B2 (en)	2010-03-30
ES2378303T3 (es)	2012-04-11
PT1469859E (pt)	2012-03-06
KR100874505B1 (ko)	2008-12-18
DK1469859T3 (da)	2012-03-19
KR20040089127A (ko)	2004-10-20
US20150202165A1 (en)	2015-07-23
GB0202002D0 (en)	2002-03-13
WO2003063878A1 (en)	2003-08-07
US20100152293A1 (en)	2010-06-17
AU2003206999B2 (en)	2007-12-13
US20130324613A1 (en)	2013-12-05
US8524776B2 (en)	2013-09-03
NO20043548L (no)	2004-08-25
CN1678323A (zh)	2005-10-05
CA2473687C (en)	2011-04-12

Similar Documents

Publication	Publication Date	Title
ATE535245T1 (de)	2011-12-15	Verwendung von mehrfach ungesättigten ketonen zur behandlung der psoriasis
DE60335997D1 (de)	2011-03-24	Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
DE60231804D1 (de)	2009-05-14	Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen
SE0301886D0 (sv)	2003-06-25	New use V
BRPI0006634B8 (pt)	2021-05-25	composição tópica compreendendo extrato de matricária no tratamento e prevenção de distúrbios inflamatórios
ATE462427T1 (de)	2010-04-15	Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
ATE422357T1 (de)	2009-02-15	Verwendung von allopurinol zur behandlung von bluthochdruck
DE60112766D1 (de)	2005-09-22	Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
BR0213100A (pt)	2004-11-30	Combinações para o tratamento de distúrbios imuniinflamatórios
DE60140871D1 (de)	2010-02-04	Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
DE602004023762D1 (de)	2009-12-03	Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
ATE390130T1 (de)	2008-04-15	Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
ATE425752T1 (de)	2009-04-15	Verwendung von pipamperon und einem sndri, snri oder ssri zur behandlung von stimmungs- oder angststírungen
DE602006020775D1 (de)	2011-04-28	Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von manie und bipolaren störungen
DE60011794D1 (de)	2004-07-29	Verwendung von docetaxel für die behandlung von hepatozelluläre krebs
ATE415965T1 (de)	2008-12-15	Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
DE602004030661D1 (de)	2011-02-03	Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE178486T1 (de)	1999-04-15	Verwendung von kardiotonischen mitteln und inhibitoren der stickstoffoxidsynthese zur linderung von pathologisch verringertem blutdruck
ATE486612T1 (de)	2010-11-15	Verfahren zur behandlung von diabetes typ 2
ATE315387T1 (de)	2006-02-15	Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
SE0301885D0 (sv)	2003-06-25	New use IV
DE60128084D1 (de)	2007-06-06	Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE60220825D1 (de)	2007-08-02	Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
MXPA04011018A (es)	2005-01-25	Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
SE0301884D0 (sv)	2003-06-25	New use III